Clinical trials investigating plerixafor and other agents targeting CXCR4, including anti-CXCR4 monoclonal antibodies and peptide CXCR4 antagonists, for leukemia and lymphoma are currently under way [32]. Here, CXCR4 is linked to leukemia.